Uric Acid: Is Lower Better? There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs? https://t.co/W5FsDC5FG0 https://t.co/7mRgkg00uV

• Uric Acid: Is Lower Better? | RheumNow

Updated Algorithm for the Management of Restless Legs Syndrome Diagnose: chronic vs intermittent RLS (no need for polysomnography) Test Iron levels (& Rx if) Consider: remove exacerbators; walking/massage/heat; carbidopa/ levodopa; pramipexole or ropinirole; low potency opioids; https://t.co/XdzIipw1X8

True or False: EULAR recommends glucocorticoids alone, without additional agents, for remission induction in life-threatening ANCA-associated vasculitis. Did you get it right? Take this week's RheumIQ quiz at https://t.co/TBlB4pmnKa. https://t.co/4IsId6lJ4Y

• RheumIQ Weekly Quiz | RheumNow

True or False: There is an available antidote for colchicine overdose. Check your answer in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/RgJ4xEAuZA

• RheumIQ Weekly Quiz | RheumNow

The mortality gap in gout has not improved in 20 years – CV disease is the leading cause of death (2-fold increase). For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/c12GmMaatt

• Gout Campaign - July 2026 | RheumNow

QD Clinic: Cellulitis Paradoxes Dr. Richard Conway, Dublin, discusses a case of cellulitis and gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026. https://t.co/ZeYyISJrrE https://t.co/2Ih4QRa7FK

• QD Clinic: Cellulitis Paradoxes | RheumNow

FDA Delays Gout Drug NASP with Complete Response Letter On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p

Non-gout drugs that may lower uric acid – losartan, amlodipine, ACE inhibitors, fenofibrate, atorvastatin, leflunomide, vitamin C, estrogen, and high-dose ASA. For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/vmNvqojAcS

• Gout Campaign - July 2026 | RheumNow

Problems with treatment adherence in the management of gout Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%. This https://t.co/OoLh0HUUH2

🎥 In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know. Watch now: https://t.co/KQmkdziLF5 #Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00

• Systemic Burden of Gout | RheumNow

Netherlands pragmatic open-label RCT from 8 rheum centres tested T2T vs Sx Rx in 308 Gout pts starting ULT (87% male; 66 yrs). Remission (no flares & pain < 2) betw 18-24 mos was more in T2T pts (39% vs 24%; p=0.02), but more AE w/ Sx driven Rx (53 vs 42%) https://t.co/5g2dY5y900

Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://t.co/S5Eg4AZSPU https://t.co/nG2p2g2Jc1

• The prevalence and incidence of Raynaud’s in England, United Kingdom